Assignee
NAVIRE PHARMA INC
US·4 granted patents·4 pending applications·41 citations·filing 2019–2024
Top patents by PatentIndex Score
8 records- 0195US10954243B2Substituted heterocyclic inhibitors of PTPN11NAVIRE PHARMA INC·Filed 2019·Granted Mar 23, 2021·35 cites·18 claims
- 0287US11104675B2PTPN11 inhibitorsNAVIRE PHARMA INC·Filed 2019·Granted Aug 31, 2021·6 cites·24 claims
- 0380US2025188074A1Ptpn11 inhibitorsNAVIRE PHARMA INC·Filed 2024·Application pending·0 cites
- 0474US11945815B2PTPN11 inhibitorsNAVIRE PHARMA INC·Filed 2021·Granted Apr 2, 2024·0 cites·16 claims
- 0561US11932643B2Substituted heterocyclic inhibitors of PTPN11NAVIRE PHARMA INC·Filed 2021·Granted Mar 19, 2024·0 cites·21 claims
- 0654US2025195520A1Combination therapy using a ptpn11 inhibitor and an egfr inhibitorNAVIRE PHARMA INC·Filed 2022·Application pending·0 cites
- 0753US2025009748A1Combination therapy using substituted pyrimidin-4(3h)-ones and sotorasibNAVIRE PHARMA INC·Filed 2022·Application pending·0 cites
- 0851US2025213563A1Substituted pyrimidin-4(3h)-ones for use in treating cancerNAVIRE PHARMA INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NAVIRE PHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →